JP7686096B2 - ドーパミンｄ３／ｄ２受容体調節化合物 - Google Patents

ドーパミンｄ３／ｄ２受容体調節化合物 Download PDF

Info

Publication number
JP7686096B2
JP7686096B2 JP2024001696A JP2024001696A JP7686096B2 JP 7686096 B2 JP7686096 B2 JP 7686096B2 JP 2024001696 A JP2024001696 A JP 2024001696A JP 2024001696 A JP2024001696 A JP 2024001696A JP 7686096 B2 JP7686096 B2 JP 7686096B2
Authority
JP
Japan
Prior art keywords
compound
formula
compounds
pharma
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024001696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024098972A (ja
JP2024098972A5 (enExample
Inventor
ボルザ，イシュトバーン
エーレシュ，ヤーノシュ
メンツィンガー，バーリント
ボッドナールネ・ディーク，シルビア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2024098972A publication Critical patent/JP2024098972A/ja
Publication of JP2024098972A5 publication Critical patent/JP2024098972A5/ja
Priority to JP2025083110A priority Critical patent/JP2025122072A/ja
Application granted granted Critical
Publication of JP7686096B2 publication Critical patent/JP7686096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024001696A 2023-01-11 2024-01-10 ドーパミンｄ３／ｄ２受容体調節化合物 Active JP7686096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025083110A JP2025122072A (ja) 2023-01-11 2025-05-19 ドーパミンｄ３／ｄ２受容体調節化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11
US63/479,530 2023-01-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025083110A Division JP2025122072A (ja) 2023-01-11 2025-05-19 ドーパミンｄ３／ｄ２受容体調節化合物

Publications (3)

Publication Number Publication Date
JP2024098972A JP2024098972A (ja) 2024-07-24
JP2024098972A5 JP2024098972A5 (enExample) 2025-02-10
JP7686096B2 true JP7686096B2 (ja) 2025-05-30

Family

ID=89573273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024001696A Active JP7686096B2 (ja) 2023-01-11 2024-01-10 ドーパミンｄ３／ｄ２受容体調節化合物
JP2025083110A Pending JP2025122072A (ja) 2023-01-11 2025-05-19 ドーパミンｄ３／ｄ２受容体調節化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025083110A Pending JP2025122072A (ja) 2023-01-11 2025-05-19 ドーパミンｄ３／ｄ２受容体調節化合物

Country Status (13)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
CN (1) CN120569367A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (1) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
MX (1) MX2025008101A (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501215A (ja) 2003-08-04 2007-01-25 リヒター ゲデオン ベジェセティ ジャール アールテー． Ｄ３／ｄ２受容体アンタゴニストとしての（チオ）カルバモイル−シクロヘキサン誘導体
JP2023501306A (ja) 2019-11-05 2023-01-18 上▲海▼翰森生物医▲薬▼科技有限公司 ベンゾチオフェン誘導体レギュレーター、その調製法及び使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN118772126A (zh) 2019-10-29 2024-10-15 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501215A (ja) 2003-08-04 2007-01-25 リヒター ゲデオン ベジェセティ ジャール アールテー． Ｄ３／ｄ２受容体アンタゴニストとしての（チオ）カルバモイル−シクロヘキサン誘導体
JP2023501306A (ja) 2019-11-05 2023-01-18 上▲海▼翰森生物医▲薬▼科技有限公司 ベンゾチオフェン誘導体レギュレーター、その調製法及び使用

Also Published As

Publication number Publication date
KR20240112213A (ko) 2024-07-18
TW202432139A (zh) 2024-08-16
CN120569367A (zh) 2025-08-29
JP2024098972A (ja) 2024-07-24
JP2025122072A (ja) 2025-08-20
US12168007B1 (en) 2024-12-17
GEAP202516807A (en) 2025-08-25
US20250049786A1 (en) 2025-02-13
WO2024150068A3 (en) 2024-08-22
CL2025002035A1 (es) 2025-10-03
WO2024150068A2 (en) 2024-07-18
IL321654A (en) 2025-08-01
MX2025008101A (es) 2025-08-01
AU2024208533A1 (en) 2025-07-10
CO2025010725A2 (es) 2025-08-29
AR131577A1 (es) 2025-04-09
EP4400495A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP5437473B2 (ja) Ａｍｐａ及びｎｍｄａ受容体モジュレーターとして使用するベンゾチアジアゼピン誘導体
EP1599167B1 (fr) Derives de benzimidazole et d'imidazo-pyridine ayant une affinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
US6586435B2 (en) Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
CA2232116C (fr) Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1100795B1 (de) Disubstituierte bicyclische heterocyclen mit insbesondere eine thrombinhemmende wirkung
Van der Walt et al. 1, 3, 7-Triethyl-substituted xanthines—possess nanomolar affinity for the adenosine A1 receptor
WO2001032615A1 (en) 1,4 substituted piperidinyl nmda/nr2b antagonists
DE602005003128T3 (de) Chinazolinon-derivate als vanilloid-antagonisten
KR20040063144A (ko) 단백질 키나제 억제제로서 유용한 벤즈이미다졸
DE4332168A1 (de) Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP7125495B2 (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
WO2011140333A1 (en) Identification of stabilizers of multimeric proteins
CZ265096A3 (en) Thienoindole derivatives, their use, process of their preparation and pharmaceutical composition containing thereof
CA2645211A1 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
EP2582670A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
BR112017028492B1 (pt) Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
AU2003210212A1 (en) Quinazolinone derivatives and their use as cb agonists
Baraldi et al. 7-Substituted-pyrrolo [3, 2-d] pyrimidine-2, 4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: a promising approach for treating pain and inflammation
JP7686096B2 (ja) ドーパミンｄ３／ｄ２受容体調節化合物
Webb et al. Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors
WO2008157407A2 (en) Thiadiazole, oxadiazole and triazole derivatives for treating leukemia
KR102921799B1 (ko) 도파민 d3/d2 수용체 조절 화합물
IE911329A1 (en) Heterocyclic compounds and their preparation and use
Bojarski et al. Structure–intrinsic activity relationship studies in the group of 1-imido/amido substituted 4-(4-arylpiperazin-1-yl) cyclohexane derivatives; new, potent 5-HT1A receptor agents with anxiolytic-like activity
HK40114011A (en) Dopamine d3/d2 receptor modulating compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250520

R150 Certificate of patent or registration of utility model

Ref document number: 7686096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150